Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-02-19
1998-09-22
Elliott, George C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4353201, A61K 4800, C12N 1564
Patent
active
058114076
ABSTRACT:
The present invention provides a method of delivering immunogenic or therapeutic proteins to bone marrow cells using alphavirus vectors. The alphavirus vectors disclosed herein target specifically to bone marrow tissue, and viral genomes persist in bone marrow for at least three months post-infection. No or very low levels of virus were detected in quadricep, brain, and sera of treated animals. The sequence of a consensus Sindbis cDNA clone, pTR339, and infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed. The sequence of the genomic RNA of the Girdwood S.A. virus, and cDNA clones, infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed.
REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5505947 (1996-04-01), Johnston et al.
GenBank Sequence of Girwood, S.A. (complete genome). Released Jan. 30, 1996.
McKnight et al.; Deduced Consensus Sequence of Sindbis Virus Strain AR339: Mutations Contained in Laboratory Strains Which Affect Cell Culture and In Vivo Phenotyples, J. of Virology, 70(3):1981-1989 (1996).
Simpson et al.; Complete Nucleotide Sequence and Full-Length cDNA Clone of S.A.AR86, a South African Alphavirus Related to Sindbis, Virology, 222(Article No. 445):464-469 (1996).
Bredenbeek et al.; Sindbis Virus Expression Vectors: Packaging of RNa Replicons by Using Defective Helper RNAs, J. of Virology, 67(11):6439-6446 (1993).
Davis et al.; Attenuated Mutants of Venezuelan Equine Encephalitis Virus Containing Lethal Mutations in the PE2 Cleavage Signal Combined with a Second-Site Suppressor Mutation in E1, Virology, 212:102-110 (1995).
Davis et al; A Genetically Engineered Live Virus Vaccine for Venezuelan Equine Encephalitis (Abstract N404), J. Cell Biochemistry, Supplement 0 No. 17 Part D: 79 (1993).
Davis et al.; Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone, Virology, 183:20-31 (1991).
Frolov et al.; Alphavirus-based expression vectors: Strategies and applications, Proc., Natl. Acad. Sci. USA, 93:11371-11377 (1996).
Liljestrom et al.; A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon, Bio/Technology, Research, 9:1356-1361 (1991).
Morgenstern et al.; Advanced mammalian gene transfer: high titre retroviral vectors wit multiple drug selection markers and a complementary helper-free packaging cell line, Nucleic Acids Research, 18(12):3587-3596 (1990).
Polo et al.; Attenuating Mutations in Glycoproteins E1 and E2 of Sindbis Virus Produce a Highly Attenuated Strain When Combined In Vitro, J. of Virology, 64(9):4438-4444 (1990).
Schoepp et al.; Directed Mutagenesis of a Sindbis Virus Pathogenesis Site, Virology, 193:149-159 (1993).
Strauss et al.; The Alphaviruses: Gene Expression, Replication, and Evolution, Biological Reviews, 58(3):491-562 (1994).
Suomalainen et al.; Spike Protein-Nucleocapsid Interactions Drive the Budding of Alphavirus, J. of Virology, 66(8):4737-4747 (1992).
Hahn et al., "Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation"; Proc. Natl. Acad. Sci. USA, 89:2679-2683 (1992).
London et al., "Infectious enveloped RNA virus antigenic chimeras"; Proc. Natl. Acad. Sci. USA, 89:207-211 (1992).
Davis Nancy L.
Johnston Robert E.
Simpson Dennis A.
Brusca John S.
Elliott George C.
The University of North Carolina at Chapel Hill
LandOfFree
System for the in vivo delivery and expression of heterologous g does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System for the in vivo delivery and expression of heterologous g, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System for the in vivo delivery and expression of heterologous g will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1621887